Stocktoria
INVO Fertility, Inc. IVF
INVO Fertility, Inc. (IVF) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $6.8M at a -340.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | -0.374 |
| Retained earnings / assets | -4.519 |
| EBIT / assets | -0.358 |
| Equity / liabilities | 0.556 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| IVF | INVO Fertility, Inc. | 4/9 | -19.01 | — | — |
| XAIR | Beyond Air, Inc. | 5/9 | — | — | — |
| PSTV | PLUS THERAPEUTICS, INC. | 3/9 | — | — | — |
| LUCD | Lucid Diagnostics Inc. | 3/9 | — | — | — |
| NSPR | InspireMD, Inc. | 3/9 | -10.12 | — | — |
| NMTC | NEUROONE MEDICAL TECHNOLOGIES Corp | 5/9 | -19.57 | — | — |
| MDNC | Medinotec Inc. | 5/9 | — | 74 | — |
About INVO Fertility, Inc.
INVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients. It operates through Fertility Clinic Services and INVOcell Device segments. The company offers INVOcell Device, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. It also operates fertility clinics, including INVO Centers. The company was formerly known as NAYA Biosciences, Inc. and changed its name to INVO Fertility, Inc. in April 2025. INVO Fertility, Inc. was founded in 2007 and is based in Sarasota, Florida.
FAQ
Is IVF financially healthy?
INVO Fertility, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does IVF pay a dividend?
No, INVO Fertility, Inc. does not currently pay a dividend.
How profitable is IVF?
In FY2025, INVO Fertility, Inc. had a net margin of -340.9% and a return on equity of -322.8%.
What is the analyst price target for IVF?
The average Wall-Street price target for INVO Fertility, Inc. is $20.00, about 1880.2% above the recent price, from 1 analysts.
Is IVF a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on INVO Fertility, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.